Table 3 Clinical responses to dasatinib and nilotinib in CML treatment
From: P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
Patients | McyR(%) | CCyR (%) | PFS (%) | OS (%) | ||||
|---|---|---|---|---|---|---|---|---|
| Â | DAS | NIL | DAS | NIL | DAS | NIL | DAS | NIL |
Imatinib-resistant | 55 | 48 | NR | 30 | 75 | NR | 92 | NR |
Imatinib-intolerant | 78 | 47 | 78 | 35 | 94 | NR | 100 | NR |
All patients | 62 | 48 | 53 | 31 | 80 | NR | 94 | NR |